Innovative, long-acting treatments – for patients and society
Camurus is committed to improving the lives of patients with severe and chronic diseases
Learn moreUpdates
Latest news
Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2026/2029
Resolutions at the annual general meeting 2026 in Camurus
Camurus to present at Jefferies Global Healthcare Conference

Disease areas
Focus on severe and chronic diseases
Developing treatments for diseases within the central nervous system, rare diseases, endocrinology, oncology and supportive care.
Events
Upcoming events
-
03Jun
Handelsbanken Nordic Small & Mid Cap Seminar 2026
Camurus’ Chief Business Development Officer Fredrik Joabsson is presenting at this conference in Stockholm, 3 June, at 12.30pm CET. The presentation can be seen by the conference participants.
-
03Jun
Jefferies Global Healthcare Conference
Camurus’ President & CEO Fredrik Tiberg is presenting at this conference in New York, 3 June at 10.55pm CET. Webcast.
-
22Jun
BIO International Convention 2026
Camurus will participate in this conference in San Diego, CA, US, 22-25 June, 2026.
Annual General Meeting
Camurus’ Annual General Meeting 2026 will be held at 5:00 pm CEST on 28 May 2026 at The Loop, Rydbergs torg 4, SE-224 84, Lund, Sweden.
Notification of attendance at the AGM:
https://www.euroclear.com/sweden/generalmeetings/
Documents:
See documents for Annual General Meeting 2026
See more information on Camurus general meetings

Latest financial report
Camurus’ Interim Report January-March 2026
12 May 2026
Annual Report 2025

Pipeline
Diversified pipeline with large potential
Camurus’ innovative product candidates are designed to address important unmet medical needs, with the potential to make significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.
Sustainability
Sustainable solutions for a healthier world
Ensuring the long-term successful development of our business – for the benefit of patients, healthcare systems, employees and shareholders.





